Skip to main content

Table 4 Prediction of post modification sites for both N55A and N55B proteins of two genotypes of 1a and 3a

From: First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

Genotypes Phosphorylation
N55A 1a 99 T, 103 S, 106 Y, 117 S, 118 Y, 129 Y, 134 T, 181 S, 201 S, 207 S, 222 S, 225 S, 229 S, 232 S
N55A 3a 99 T, 114 S,118 Y, 129 Y,131 S,146 S,200 T,207 S, 222 S,225 S
N55B 1a 64 Y, 103 Y, 335 S, 346 Y, 347 S, 399 T, 506 S, 513 S, 561 Y
N55B 3a 34 S, 56 S, 106 S, 113 Y, 114 S, 122 S, 142 T, 357 S, 395 T, 409 T
Genotypes Glycosylation
NS5A 1a 69
NS5A 3a 69,103,105
NS5B 1a 369
NS5B 3a 379, 545
Genotypes Disulfide bonds
NS5A 1a 39–59, 39–140, 39–142, 39–190, 98 –165
NS5A 3a 39–57, 39–59, 57–140, 101–165, 142–190
NS5B 1a 14–46, 146–170, 243–279, 242–274, 324–366, 521–575
NS5B 3a 9–156, 24–99, 233–253, 252–284, 272–305, 326–376, 504–531
  1. Results showed several phosphorylation and glycosylation sites as well as disulfide bonds in both proteins